Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

Quick Stats
Studies 178
Trials 100
Score 1
2022 pubmed 15 citations

Clinical use of Anti-Müllerian Hormone to monitor resumption of ovarian activity following removal of a 4.7 mg deslorelin implant in queens.

Ferré-Dolcet. L L; Ferro. S S; Contiero. B B; Fontaine. C C; Badon. T T; Gelli. D D; Romagnoli. S S

Key Findings

  • AMH levels drop sharply during deslorelin treatment and reach a low point one week after implant removal
  • AMH levels rise after removal and return to pre‑treatment levels by week 6
  • The timing of AMH recovery is similar whether the implant was in for 3, 6 or 9 months, but adult cats have lower AMH overall

Practical Outcomes

  • For cat breeders, measuring AMH can help predict when a queen will become fertile again after taking out a deslorelin implant. This insight is specific to feline reproductive management and doesn’t translate into direct protocols for human longevity or performance optimization.

Summary

Researchers studied cats that had a hormone implant (deslorelin) removed and measured a blood marker (AMH) to see when their ovaries started working again. AMH fell during treatment, hit its lowest point a week after removal, and went back up to normal levels by about six weeks, regardless of how long the implant had been in place.

Abstract

The use of deslorelin implants to control reproduction in cats is increasing but because of its prolonged duration, cat breeders often request implant removal before the end of the treatment. Assaying Anti Mullerian Hormone (AMH) concentrations might be useful to predict time of resumption of ovarian activity in deslorelin-treated queens following implant removal. In queens a minimum of 3 weeks during increasing photoperiod after implant removal has been described for resumption of ovarian activity but no information about AMH concentrations were observed for determining ovarian activity. Sixteen queens in which deslorelin implants were surgically removed after 3, 6 or 9 months (n = 6, 4 and 6 queens, respectively) were used in this study. A general and reproductive health check with a GnRH stimulation test were performed before the treatment. After implant removal queens were checked every 1-2 weeks with reproductive ultrasonography, a vaginal smear and blood collection to assay AMH concentrations. AMH concentrations decreased significantly at the end of the treatment to ≤ 2.5 + 0.6 ng/ml (p ≤ 0.05) and reached a nadir at 1.9 ± 0.9 (p < 0.05) one-week post-removal. Following implant removal AMH concentrations started to rise reaching a value of 3.9 ± 0.7 ng/ml on the third week and were not different from pre-treatment levels on week 6 post-removal (5.8 ng/ml + 0.9, p ≥ 0.05). AMH values did not differ depending on duration of deslorelin treatment but were lower in adult queens (p < 0.05). AMH assay can be a useful tool to follow resumption of feline ovarian function following a deslorelin treatment.

Study Information

Provider

pubmed

Year

2022

Date

2022-03-26T00:00:00.000Z

DOI

10.1007/s11259-022-09919-2

Citations

15

References

33